Boston Scientific met Q1 EPS expectations and beat sales estimates with 11.6% revenue growth, but management cut its 2026 outlook. The near-term earnings and revenue print are positive, but the reduced longer-term guidance tempers the message. Shares still rose in premarket trading, suggesting investors are focusing on the strong quarter over the outlook cut.
Boston Scientific met Q1 EPS expectations and beat sales estimates with 11.6% revenue growth, but management cut its 2026 outlook. The near-term earnings and revenue print are positive, but the reduced longer-term guidance tempers the message. Shares still rose in premarket trading, suggesting investors are focusing on the strong quarter over the outlook cut.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
